Kurse werden geladen...
Prognose
Kaufen | 8 |
Halten | 4 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -6 / 13 |
News
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible for leading Cassava's research and development efforts.» Mehr auf globenewswire.com
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer.» Mehr auf globenewswire.com
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.» Mehr auf zacks.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 0,00 | 100,00% |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −26,52 Mio | 40,15% |
EBITDA | −26,27 Mio | 29,46% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 68,87 Mio€ |
Anzahl Aktien | 48,31 Mio |
52 Wochen-Hoch/Tief | 37,37€ - 1,02€ |
Dividenden | Nein |
Beta | -1,48 |
KGV (PE Ratio) | −3,18 |
KGWV (PEG Ratio) | 0,12 |
KBV (PB Ratio) | 0,53 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Cassava Sciences, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt Medikamente für neurodegenerative Krankheiten. Der führende therapeutische Produktkandidat ist Simufilam, ein niedermolekulares Medikament, das sich in der klinischen Phase 2b befindet, und der diagnostische Produktkandidat ist SavaDx, ein blutbasierter Biomarker/Diagnostikum zur Erkennung der Alzheimer-Krankheit. Das Unternehmen war früher als Pain Therapeutics, Inc. bekannt und änderte im März 2019 seinen Namen in Cassava Sciences, Inc. Cassava Sciences, Inc. wurde 1998 gegründet und hat seinen Sitz in Austin, Texas.
Name | Cassava Sciences |
CEO | Richard Jon Barry |
Sitz | Austin, tx USA |
Website | |
Industrie | Biotechnologie |
Börsengang | |
Mitarbeiter | 30 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | SAVA |
Frankfurt | PX91.F |
Düsseldorf | PX91.DU |
München | PX91.MU |
Assets entdecken
Shareholder von Cassava Sciences investieren auch in folgende Assets